These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 13807568)

  • 41. Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.
    Murray HW; Hariprashad J
    Antimicrob Agents Chemother; 1996 Mar; 40(3):586-7. PubMed ID: 8851575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Fungistatic, pharmacodynamic and therapeutic activity of 3,5-dichloro-4'-fluorothiocarbanilide].
    VANBREUSEGHEM R; BUU-HOI NP; XUONG ND; LAMBELIN G
    Biochem Pharmacol; 1962 Sep; 11():813-22. PubMed ID: 13924659
    [No Abstract]   [Full Text] [Related]  

  • 43. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.
    Sundar S; Agrawal NK; Sinha PR; Horwith GS; Murray HW
    Ann Intern Med; 1997 Jul; 127(2):133-7. PubMed ID: 9230003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leishmania strains causing self-healing cutaneous leishmaniasis have greater susceptibility towards oxidative stress.
    Sarkar A; Ghosh S; Pakrashi S; Roy D; Sen S; Chatterjee M
    Free Radic Res; 2012 May; 46(5):665-73. PubMed ID: 22385212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative toxicity and efficacy of urea stibamines in experimental leishmaniasis.
    REED RK; MAR J; ANDERSON HH
    Fed Proc; 1946; 5(1 Pt 2):197. PubMed ID: 21064435
    [No Abstract]   [Full Text] [Related]  

  • 46. [A case report of visceral leishmaniasis].
    Popov G; Andreeva N; Georgiev A; Kuzmanova E
    Vutr Boles; 1991; 30(2):121-5. PubMed ID: 1654012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Observations on the treatment of 25 cases of kala-azar with stibatin (sodium antimony gluconate).
    CHOUDHURI RK
    Ind Med Gaz; 1946; 81(4-5):174-6. PubMed ID: 20291436
    [No Abstract]   [Full Text] [Related]  

  • 48. CHEMOTHERAPY OF TROPICAL DISEASES.
    TELLA A
    Curr Med Drugs; 1964 Jun; 4(10):3-8. PubMed ID: 14169083
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemotherapeutic studies on a new antifungal agent, X-5079C, effective against systemic mycoses.
    GRUNBERG E; BERGER J; TITSWORTH E
    Am Rev Respir Dis; 1961 Oct; 84():504-6. PubMed ID: 13709238
    [No Abstract]   [Full Text] [Related]  

  • 50. KALA AZAR IN LEBANON. REVIEW OF 72 CASES.
    BITAR J; NACHMAN H
    J Med Liban; 1964; 17():257-68. PubMed ID: 14252819
    [No Abstract]   [Full Text] [Related]  

  • 51. [Two cases of kala-azar treated with glucantime].
    MATOS J; VELASCO JA
    Acta Pediatr Esp; 1955 Nov; 13(155):959-63. PubMed ID: 13301754
    [No Abstract]   [Full Text] [Related]  

  • 52. THE HUMAN TRYPANOSOMATIDAE. III. LEISHMANIASIS: KALA-AZAR.
    CAHILL KM
    N Y State J Med; 1963 Dec; 63():3405-9. PubMed ID: 14083434
    [No Abstract]   [Full Text] [Related]  

  • 53. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.
    Berman JD
    Rev Infect Dis; 1988; 10(3):560-86. PubMed ID: 3293160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-Kala-Azar dermal leishmaniasis; a report of two typical cases with special reference to result of intensive antimonial therapy.
    TZU-TA C; PANG-MU C; LEE-SHIH L
    Chin Med J; 1953; 71(5):334-42. PubMed ID: 13127100
    [No Abstract]   [Full Text] [Related]  

  • 56. Antifungal agents.
    TAYLOR EP; D'ARCY PF
    Prog Med Chem; 1961; 1():220-55. PubMed ID: 13775584
    [No Abstract]   [Full Text] [Related]  

  • 57. A new sodium antimony gluconate for the treatment of kala-azar.
    DASTIDAR SK
    J Indian Med Assoc; 1945 Sep; 14():298. PubMed ID: 21003768
    [No Abstract]   [Full Text] [Related]  

  • 58. Agranulocytosis following antimony therapy in kala-azar.
    BRAHMACHARI PN; MAITI CR; KAR CC
    J Indian Med Assoc; 1955 Oct; 25(10):408-10. PubMed ID: 13278551
    [No Abstract]   [Full Text] [Related]  

  • 59. Drug susceptibility of Leishmania infantum (syn. Leishmania chagasi) isolates from Brazilian HIV-positive and HIV-negative patients.
    Inocêncio da Luz R; Romero GA; Dorval ME; Cruz I; Cañavate C; Dujardin JC; Van Assche T; Cos P; Maes L
    J Antimicrob Chemother; 2011 Mar; 66(3):677-9. PubMed ID: 21393233
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.